Monitor the company's cash burn rate and any announcements of drawdowns under the equity facility. The 36-month term and company-controlled timing mean dilution can occur at any time, creating persistent overhang. Watch for subsequent 8-K filings disclosing share sales.
TRAW drugs
TRAW drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $0.2510entry
- T+1 · 14h ago +3.59%α +5.50% · $0.2600
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The SEC declared effective Traws Pharma's S-1 registration (File No. 333-299644) on November 12, 2026, covering up to 135,135,135 shares for resale by Roth Principal Investments under a committed equity facility. This allows the company to sell up to $50 million of newly issued shares at a 6% discount to VWAP over 36 months, with the registered shares representing approximately 879% of current outstanding shares, creating severe dilution risk.
Key Facts
- S-1 registration declared effective on November 12, 2026
- Registration covers 135,135,135 shares for resale by Roth Principal Investments, LLC
- Shares represent approximately 879% of current outstanding shares
- Committed equity facility allows Traws to sell up to $50 million of newly issued shares
- Shares sold at 6% discount to VWAP over a 36-month term
- Company controls timing and amount of sales under the facility
- Cross-filing context shows S-3 shelf also effective, with $139.2M unsold securities carried forward
- Company had only $3.1M cash as of March 31, 2026, with stockholders' deficit of -$5.3M and going-concern qualification
Financial Impact
Up to $50 million in new share sales at 6% discount to VWAP; registered shares equal ~879% of current outstanding shares, implying massive dilution
Risk Factors
- Severe dilution to existing shareholders from potential issuance of up to 879% of current shares
- Company in financial distress with only $3.1M cash and going-concern qualification
- Persistent overhang from ability to sell shares at any time over 36 months
- Dual effective shelf registrations (S-1 and S-3) amplify potential dilution
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003532 |
| Document: 9999999995-26-003532-index.html | 9999999995-26-003532 |
| Document: 9999999995-26-003532.txt | 9999999995-26-003532 |
Track record
29 reports on TRAW
10 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +72.58% at T+60 after the May 8, 2026 report. 14 of 14 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 13, 20263d ago EFFECT Bearish 7/10 Viewing Entry $0.2510 Now $0.2500 +0.40% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.2848 Now $0.2500 −12.22% settles Dec 11
- Oct 26, 202621d ago S-1 Bearish 6/10 Entry $0.3660 Now $0.2500 +31.69% settles Nov 24
- Oct 23, 202624d ago 8-K Bearish 7/10 Entry $0.3411 Now $0.2500 +26.71% settles Nov 23
- Oct 20, 202627d ago DEFA14A Neutral 3/10 Entry $0.3760 Now $0.2500 −33.51% settles Nov 18
- Oct 20, 202627d ago DEF 14A Bearish 6/10 Entry $0.3760 Now $0.2500 +33.51% settles Nov 18
- Aug 14, 202613w ago Press Release Bearish 5/10 Entry $0.5400 to $0.5200 Now $0.2500 +53.70% ▲ +3.70% +2.18% vs SPY
- Jul 10, 202618w ago 8-K Bearish 6/10 Entry $0.6849 to $0.5400 Now $0.2500 +63.50% ▲ +21.16% +24.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers